Marker Therapeutics (MRKR) Cash from Investing Activities (2018 - 2023)
Marker Therapeutics (MRKR) posted quarterly Cash from Investing Activities of $18.8 million for Q2 2023, up 928.54% year-over-year from $1.8 million in Q2 2022, and up 16774.42% quarter-over-quarter from -$112608.0 in Q1 2023.
Marker Therapeutics (MRKR) Cash from Investing Activities (2018 - 2023) Analysis & Trends
Marker Therapeutics (MRKR) has reported Cash from Investing Activities for 6 consecutive years, with $18.8 million the latest figure, recorded in Q2 2023.
- In Q2 2023, Cash from Investing Activities rose 928.54% year-over-year to $18.8 million; the TTM figure through Dec 2023 stood at $18.7 million (up 477.42% YoY), while the FY2023 annual figure was $18.7 million, up 477.42% from the prior year.
- Cash from Investing Activities grew to $18.8 million in Q2 2023 per MRKR's latest filing, from -$112608.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $18.8 million in Q2 2023 and bottomed at -$4.1 million in Q4 2020.
- Historically, Cash from Investing Activities has averaged $53332.5 across 5 years, with a median of -$286484.5 in 2019.
- Annual changes were most pronounced in 2020 — Cash from Investing Activities slumped 31778.1% — and 2023, when it surged 928.54%.
- Marker Therapeutics' Cash from Investing Activities stood at -$12862.0 in 2019, then plunged by 31778.1% to -$4.1 million in 2020, then soared by 91.47% to -$349843.0 in 2021, then jumped by 63.6% to -$127342.0 in 2022, then jumped by 14845.12% to $18.8 million in 2023.
- Business Quant data shows MRKR's Cash from Investing Activities at $18.8 million in Q2 2023, -$112608.0 in Q1 2023, and -$127342.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 18.78 Mn |
| Jun 30, 2023 | 18.78 Mn |
| Mar 31, 2023 | -112,608.00 |
| Mar 31, 2023 | -112,608.00 |
| Dec 31, 2022 | -127,342.00 |
| Dec 31, 2022 | -127,342.00 |
| Sep 30, 2022 | -99,366.00 |
| Sep 30, 2022 | -99,366.00 |
| Jun 30, 2022 | -2.27 Mn |
| Jun 30, 2022 | -2.27 Mn |
| Mar 31, 2022 | -2.45 Mn |
| Mar 31, 2022 | -2.45 Mn |
| Dec 31, 2021 | -349,843.00 |
| Dec 31, 2021 | -349,843.00 |
| Sep 30, 2021 | -980,275.00 |
| Sep 30, 2021 | -980,275.00 |
| Jun 30, 2021 | -399,771.00 |
| Jun 30, 2021 | -399,771.00 |
| Mar 31, 2021 | -1.40 Mn |
| Mar 31, 2021 | -1.40 Mn |